Institution
Tata Memorial Hospital
Healthcare•Mumbai, India•
About: Tata Memorial Hospital is a healthcare organization based out in Mumbai, India. It is known for research contribution in the topics: Cancer & Breast cancer. The organization has 3187 authors who have published 4636 publications receiving 109143 citations.
Topics: Cancer, Breast cancer, Population, Sarcoma, Radiation therapy
Papers published on a yearly basis
Papers
More filters
••
TL;DR: A case of giant cell tumor of the patella in which, associated with local recurrence, there were simultaneous metastases to lymph nodes and lungs.
Abstract: Giant cell tumors of bone are known for their unpredictable behavior characterized occasionally even by metastases. Most metastases lodge in the lungs but other rare sites are regional lymph nodes, mediastinum, skin, scalp and the pelvis. In this case report we document a case of giant cell tumor of the patella in which, associated with local recurrence, there were simultaneous metastases to lymph nodes and lungs.
25 citations
••
TL;DR: Immature mesenchyme was seen in all the cases of IT of ovary and its presence should prompt a careful search for immature neuroepithelium, which has better prognosis than stage I IT of Ovary.
Abstract: Aim: Immature teratoma (IT) of the ovary represents 1% of all ovarian cancers and 20% of malignant ovarian germ cell tumors. This retrospective study of 28 such cases aims to look at its morphological spectrum and to study the correlation of the grade and stage of the tumor with prognosis. Materials and Methods: A retrospective study of 28 cases of IT of the ovary was done. Neuroepithelium was graded as grade I, II and III according to the standard criteria. The presence of immature mesenchyme was also looked for and similarly graded. Results: The median age for the cases was 19 years and abdominal pain was the commonest symptom. Neuroepithelium was seen in 26 cases (6 were grade I, 13 were grade II, and 7 were grade III); and two showed immature mesenchymal tissue (IM) only. IM was seen in all 28 cases, but no correlation with the grade of the IT of the ovary is found. The follow up is available in 23 cases ranging from 6 months to 78 months (median 33 months). Of these, 13 were stage I, 3 were stage II and 7 were stage III ITs. Out of 23 patients, 17 patients were alive without evidence of disease recurrence during the last follow up. Adverse events in the form of death and local recurrence occurred in 6 patients. One patient died of the disease at 7 months duration from the disease onset (stage III, grade II IT). Conclusion: Morphological spectrum of IT of ovary is varied. Immature mesenchyme was seen in all the cases of IT of ovary and its presence should prompt a careful search for immature neuroepithelium. Stage I IT of ovary has better prognosis. Combination of surgery and chemotherapy can give longer survival even in recurrent disease.
25 citations
••
TL;DR: In this paper, the cytogenetic findings of 100 patients with chronic myeloid leukemia (CML) [72 patients in chronic phase (CP) and 28 patients in blastic phase (BP)] were reported.
25 citations
••
TL;DR: An in vitro drug profiling platform for rhabdomyosarcoma, using a living biobank composed of twenty RMS patient-derived xenografts (PDX) for high-throughput drug testing and revealing a strong sensitivity towards AKT inhibitors in a subgroup of RMS is described.
Abstract: Cancer therapy is currently shifting from broadly used cytotoxic drugs to patient-specific precision therapies. Druggable driver oncogenes, identified by molecular analyses, are present in only a subset of patients. Functional profiling of primary tumor cells could circumvent these limitations, but suitable platforms are unavailable for most cancer entities. Here, we describe an in vitro drug profiling platform for rhabdomyosarcoma (RMS), using a living biobank composed of twenty RMS patient-derived xenografts (PDX) for high-throughput drug testing. Optimized in vitro conditions preserve phenotypic and molecular characteristics of primary PDX cells and are compatible with propagation of cells directly isolated from patient tumors. Besides a heterogeneous spectrum of responses of largely patient-specific vulnerabilities, profiling with a large drug library reveals a strong sensitivity towards AKT inhibitors in a subgroup of RMS. Overall, our study highlights the feasibility of in vitro drug profiling of primary RMS for patient-specific treatment selection in a co-clinical setting.
25 citations
•
TL;DR: Adjuvant chemotherapy may prove useful in improving the prognosis of these tumours and report two cases of Primary undifferentiated embryonal sarcoma of the liver.
Abstract: Primary undifferentiated embryonal of the liver in children is a rare neoplasm with dismal prognosis. Surgery is the treatment of choice. Adjuvant chemotherapy may prove useful in improving the prognosis of these tumours. We report two cases of Primary undifferentiated embryonal sarcoma of the liver.
25 citations
Authors
Showing all 3213 results
Name | H-index | Papers | Citations |
---|---|---|---|
Al B. Benson | 113 | 578 | 48364 |
Keitaro Matsuo | 97 | 818 | 37349 |
Ashish K. Jha | 87 | 503 | 30020 |
Noopur Raje | 82 | 506 | 27878 |
Muthupandian Ashokkumar | 76 | 511 | 20771 |
Snehal G. Patel | 73 | 367 | 16905 |
Rainu Kaushal | 58 | 232 | 16794 |
Ajit S. Puri | 54 | 369 | 9948 |
Jasbir S. Arora | 51 | 351 | 15696 |
Sudeep Sarkar | 48 | 273 | 10087 |
Ian T. Magrath | 47 | 107 | 8084 |
Pankaj Chaturvedi | 45 | 325 | 15871 |
Pradeep Kumar Gupta | 44 | 416 | 7181 |
Shiv K. Gupta | 43 | 150 | 8911 |
Kikkeri N. Naresh | 43 | 245 | 6264 |